Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by Conquistador1on Feb 02, 2018 12:43pm

90 Views

Post# 27490733

RE:RE:RE:RE:RE:RE:RE:RE: Share Consolidations Usually Destroy Market Capitalizati

barack,
The ONC share price has been falling since the consolidation was announced. It is normal, the market expects these bozos will do a cheap financing, and dilute the heck out of the current shareholders. The market is right.
I remember Norsat. Are you expecting a similar result? It is the one in a hundred exception.

Bullboard Posts

Unique Battery Metals opportunity in Quebec